This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Health Stocks in Motion

Shares of Cubist Pharmaceuticals (CBST) were among the best-performing health-related stocks Tuesday, rising 19% after the company said that its Cubicin antibiotic met its primary endpoints in a phase III trial.

Cubicin met its primary endpoints of non-inferiority in the intent-to-treat and per protocol populations, it said. Cubist plans to file a supplemental new drug application before the end of the year, adding Staphylococcus aureus endocarditis and bacteremia to the indication statement of Cubicin. Shares were trading up $2.03 to $12.96.

Zila (ZILA) rose 7% after the company closed on the sale of its Zilactin brand OTC lip and oral care products. Blairex Laboratories bought the oral care products for $10.3 million in cash and agreed-upon working capital adjustments. Zila said the brand is a valuable but non-strategic asset. "I am committed to maintaining focus on our core business and divesting non-strategic assets," the company's chief executive said in a statement. Zila will continue to concentrate on preventive health care technologies and products that focus on enhanced body defense and the detection of predisease states. Shares were trading up 20 cents to $2.95.

Shares of Corautus Genetics (VEGF) fell 13% after the company sold 4.7 million shares of stock to Boston Scientific (BSX) and a separate group of private investors. Corautus sold 2.6 million shares to the private group, resulting in proceeds of about $10 million. Pending shareholder approval, Boston Scientific will buy 2.1 million shares for $8 million. Both slugs of stock were sold at $3.80 a share. The $3.80 price represents a 24% discount to Monday's closing price of $5. In addition to the stock sale, Boston Scientific amended the terms of its loan agreement with Corautus, making $5 million in loan proceeds available immediately to Corautus. Once the stock deal with Boston Scientific closes, Boston's voting ownership in Corautus will be about 17%. Shares of Corautus were recently trading down 64 cents to $4.36.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,120.89 -51.79 -0.30%
S&P 500 1,989.57 -4.72 -0.24%
NASDAQ 4,526.5270 -1.1620 -0.03%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs